Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$79.33 USD

79.33
5,569,039

-2.48 (-3.03%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $79.34 +0.01 (0.01%) 6:52 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Lilly/AstraZeneca Expand Alzheimer Disease Collaboration

Eli Lilly and Company (LLY) and AstraZeneca plc (AZN) expanded their existing collaboration to develop the second treatment for Alzheimer's disease, MEDI1814

    Arpita Dutt headshot

    Pharma Stock Roundup: Drug Pricing Heat Back on Sector, Endo, Mylan, AZN to Cut Jobs

    Drug pricing is back in focus with president-elect Trump making it clear that he does not like price increases.

      AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting

      AstraZeneca plc (AZN) presented positive data from a randomized phase III study (AURA3) on its lung cancer drug Tagrisso at a lung cancer conference in Vienna, Austria.

        Sheraz Mian headshot

        Top Research Reports for Cisco, Merck & MasterCard

        Today's Research Daily features new research reports on 16 major stocks, including MasterCard (MA), Merck (MRK) and Cisco (CSCO).

          Arpita Dutt headshot

          Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

          This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

            Eric Dutram headshot

            Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?

            In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment market, and we get to the bottom of this emerging technology in the podcast so that investors can better understand why this market may deserve a closer look.

              Mark Vickery headshot

              Argument for Interest Rate Hike "Quite Strong"

              Fed Vice Chair Stanley Fischer said he is optimistic a rate hike would be manageable abroad, and that a stronger U.S. economy should help other countries.

                Tracey Ryniec headshot

                Is Brexit a Buying Opportunity?

                Value investors should keep an eye on what is going on in Great Britain right now.

                  Mark Vickery headshot

                  Market News Over Summer Vacation: PFE, AZN, TSLA, LZB

                  You know you're in a slow news cycle when the market focus is on a Janet Yellen speech that doesn't happen until Friday, and no one expects any action to come of it anyway.

                    Brian Bolan headshot

                    Low PE Stocks For This Market

                    A look at four stocks with low PE's and earnings estimate revisions that are among the best over the last four weeks.

                      Arpita Dutt headshot

                      Pharma Stock Outlook: Let's Make a Deal

                      M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.

                        Arpita Dutt headshot

                        Pharma Stock Outlook: Let's Make a Deal

                        M&As continue to play a major role in the pharma and biotech sector and are not showing any signs of slowing down.